Name: Reserpine
Brand: Selleck Chemicals
SKU: S1601
Availability: InStock
Rating: 5 (10 reviews)

Jump to

Quality Control

Batch: Purity: 99.77%

99.77

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase
Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Solubility

In vitro
Batch:

DMSO : 13 mg/mL (21.35 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (1.64mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (1.64mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	608.68	Formula	C₃₃H₄₀N₂O₉	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	50-55-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Reserpine inhibits efflux pumps and reduces sparfloxacin, moxifloxacin and ciprofloxacin IC50s and MICs by up to four-fold in 11, 21 and 48 of the 102 unrelated clinical isolates tested.
In vivo	Reserpine (5 mg/kg s.c.) reduces extracellular DA levels to 4% of basal values in intact rats. This compound diminishes L-DOPA (50 mg/kg i.p.)-induced increases in extracellular dopamine levels to 16% of those obtained in denervated animals not pretreated with reserpine in 6-hydroxydopamine-lesioned rats. It causes a marked depletion of vasopressin/oxytocin-neu-rophysin-like immunoreactivity (LI) and CRH-L1 in the median eminence of the rat. This chemical significantly restores performance on the delayed response task in monkeys. It has little effect on performance of a visual discrimination task, a reference memory task which does not depend on the prefrontal cortex. Its injection (one dose of 1 mg/kg s.c.) every other day for 3 days causes a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching in rats, compared to the control. This agent results in a decreased glutamate uptake in the subcortical parts of rats. It (5 mg/kg) significantly increases vacuous jaw movements, and also reduces rearing behavior in all age groups of rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10052906/ [2] https://pubmed.ncbi.nlm.nih.gov/10617128/ [3] https://pubmed.ncbi.nlm.nih.gov/1850078/ [4] https://pubmed.ncbi.nlm.nih.gov/8102313/ [5] https://pubmed.ncbi.nlm.nih.gov/15649445/ [6] https://pubmed.ncbi.nlm.nih.gov/8265695/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-03-05)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06199778	TERMINATED	Traumatic Brain Injury	Zeng Changhao	2022-06-01
NCT03223272	COMPLETED	Refractory Hypertension	University of Alabama at Birmingham	2015-07-23	PHASE2
NCT02684786	WITHDRAWN	Pulmonary Artery Hypertension	Mayo Clinic	2016-07	PHASE1
NCT00000499	COMPLETED	Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases	National Heart, Lung, and Blood Institute (NHLBI)	1980-09	PHASE2
NCT00000514	COMPLETED	Cardiovascular Diseases; Cerebrovascular Disorders; Heart Diseases; Hypertension	National Heart, Lung, and Blood Institute (NHLBI)	1984-06	PHASE3
NCT00267657	UNKNOWN	Amphetamine-Related Disorders	National Institute on Drug Abuse (NIDA)	2004-01	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Reserpine VMAT inhibitor

Chemical Structure

Molecular Weight: 608.68